FARE - Food Allergy Research & Education Logo

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Study Purpose

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 4 Years - 17 Years
Gender All
More Inclusion & Exclusion Criteria


Inclusion Criteria:

  • - Physician-diagnosed immunoglobulin E (IgE) mediated peanut allergy; - Peanut specific serum IgE measured by ImmunoCAP® ≥ 0.7 kilounit allergy specific antibody per litre (kUA/L) at screening; - Positive skin prick test to peanut with mean wheal diameter ≥5 mm greater than negative control at screening; - Positive peanut double blind placebo-controlled food challenge (DBPCFC) with a reactive dose ≤300 mg peanut protein (≤443 mg cumulative reactive dose [CRD]); - Able to perform spirometry or peak expiratory flow.
Children who are 4 years of age at Screening Stage 1 visit and unable to perform peak expiratory may be enrolled providing they had no clinical features of moderate or severe persistent asthma within 1 year prior to the Screening visit;
  • - Forced expiratory volume in 1 second (FEV1) ≥80% predicted in adolescents and children with asthma capable of performing spirometry, or peak expiratory flow ≥80% predicted in participants with asthma unable to perform spirometry (at investigator's discretion).

Exclusion Criteria:

  • - History of or current clinically significant medical conditions or laboratory abnormalities which in the opinion of the investigator would jeopardise the safety of the participant or the validity of the study results; - Severe or unstable asthma as assessed by the Global Initiative for Asthma (GINA) assessment of asthma control OR current treatment for asthma at GINA ≥Step 4 level; - Participants with skin disorders that would hinder skin prick testing and/or its interpretation or study drug administration (eg, severe generalised poorly controllable atopic dermatitis); - Any medical condition in which epinephrine (adrenaline) is contraindicated; - Prior therapy aimed at desensitising peanut allergy, either in a formal study or in clinical practice; - Severe or life-threatening reaction during the screening food challenge, at investigator discretion.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Aravax Pty Ltd
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Brian Vickery, MD
Principal Investigator Affiliation Emory University
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries Australia, United States

The disease, disorder, syndrome, illness, or injury that is being studied.

Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Arms & Interventions


Experimental: PVX108 50 nmol in adolescents

Twelve 4-weekly intradermal (ID) doses of PVX108 at 50 nmol in adolescents (Cohort 1)

Placebo Comparator: Placebo in adolescents

Twelve 4-weekly ID doses of placebo matching PVX108 in adolescents (Cohort 1)

Experimental: PVX108 5 nmol in children

Twelve 4-weekly ID doses of PVX108 at 5 nmol in children (Cohort 2)

Experimental: PVX108 50 nmol in children

Twelve 4-weekly ID doses of PVX108 at 50 nmol in children (Cohort 2)

Placebo Comparator: Placebo in children

Twelve 4-weekly ID doses of placebo matching PVX-108 in children (Cohort 2)


Biological: - PVX-108

PVX108 comprises a mixture of peptides that represent sequences from peanut allergens

Biological: - Placebo

Matching placebo comprises the formulation vehicle without peptides

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Arkansas Children's Research Institute, Little Rock, Arkansas




Arkansas Children's Research Institute

Little Rock, Arkansas, 72202

Peninsula Research Associates, Rolling Hills Estates, California




Peninsula Research Associates

Rolling Hills Estates, California, 90274

Children's Healthcare of Atlanta, Atlanta, Georgia




Children's Healthcare of Atlanta

Atlanta, Georgia, 30329

Johns Hopkins Hospital, Baltimore, Maryland




Johns Hopkins Hospital

Baltimore, Maryland, 21205

Site Contact




Massachusetts General Hospital, Boston, Massachusetts




Massachusetts General Hospital

Boston, Massachusetts, 02114

Site Contact




Chapel Hill, North Carolina




University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599

International Sites

Sydney Children's Hospital, Randwick, New South Wales, Australia




Sydney Children's Hospital

Randwick, New South Wales,

The Children's Hospital at Westmead, Westmead, New South Wales, Australia




The Children's Hospital at Westmead

Westmead, New South Wales,

Women's and Children's Hospital, North Adelaide, South Australia, Australia




Women's and Children's Hospital

North Adelaide, South Australia,

The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia


Active, not recruiting


The Royal Children's Hospital Melbourne

Parkville, Victoria,

Perth Children's Hospital, Nedlands, Western Australia, Australia




Perth Children's Hospital

Nedlands, Western Australia,

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.